Net Worth Advisory Group Has $691,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Net Worth Advisory Group cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 895 shares of the company’s stock after selling 24 shares during the period. Net Worth Advisory Group’s holdings in Eli Lilly and Company were worth $691,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in LLY. Principal Financial Group Inc. grew its stake in shares of Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after purchasing an additional 60,306 shares during the period. XML Financial LLC grew its stake in shares of Eli Lilly and Company by 1.0% during the third quarter. XML Financial LLC now owns 1,775 shares of the company’s stock worth $1,572,000 after purchasing an additional 17 shares during the period. Arvest Investments Inc. grew its stake in Eli Lilly and Company by 5.1% in the third quarter. Arvest Investments Inc. now owns 870 shares of the company’s stock valued at $771,000 after acquiring an additional 42 shares during the period. Los Angeles Capital Management LLC grew its stake in Eli Lilly and Company by 0.9% in the third quarter. Los Angeles Capital Management LLC now owns 468,385 shares of the company’s stock valued at $414,961,000 after acquiring an additional 4,390 shares during the period. Finally, Ashton Thomas Securities LLC grew its stake in Eli Lilly and Company by 41.2% in the third quarter. Ashton Thomas Securities LLC now owns 3,782 shares of the company’s stock valued at $3,351,000 after acquiring an additional 1,103 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

LLY opened at $828.80 on Tuesday. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The firm has a market capitalization of $785.84 billion, a PE ratio of 70.78, a PEG ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The business’s 50-day simple moving average is $827.73 and its 200 day simple moving average is $846.36.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has initiated a stock repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LLY. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research note on Thursday, January 16th. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price for the company. Truist Financial boosted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Bank of America reissued a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.